Search

Your search keyword '"Duan,Zhongping"' showing total 757 results
Start Over Author "Duan,Zhongping"
757 results on '"Duan,Zhongping"'

151. Hepatitis B-related Acute-on-Chronic Liver Failure Induced by Hepatotropic Viral insult is Associated with Worse Prognosis Than that Induced by Non-Virus Insult

Author

Liang, Jing, primary, Liu, Lei, additional, Cao, Yingying, additional, Zhang, Qian, additional, Liu, Fang, additional, Yu, Chen, additional, Liu, Hua, additional, Duan, Zhongping, additional, Xu, Manman, additional, Xin, Shaojie, additional, You, Shaoli, additional, Song, Fangjiao, additional, Li, Jun, additional, and Han, Tao, additional

Published
2021
Full Text
View/download PDF

152. Maternal hepatitis B e antigen can be an indicator for antiviral prophylaxis of perinatal transmission of hepatitis B virus

Author

Lu, Ying, primary, Song, Yarong, additional, Zhai, Xiangjun, additional, Zhu, Fengcai, additional, Liu, Jianxun, additional, Chang, Zhanjun, additional, Li, Yi, additional, Xiao, Yiwei, additional, Li, Lili, additional, Liu, Minmin, additional, Liu, Jia, additional, Duan, Zhongping, additional, Zou, Huaibin, additional, Zhuang, Hui, additional, Wang, Jie, additional, and Li, Jie, additional

Published
2021
Full Text
View/download PDF

155. Numerical simulation of transient turbulent cavitating flows with special emphasis on shock wave dynamics considering the water/vapor compressibility

Author

Duan Zhongping, Bin Ji, Biao Huang, Wang Changchang, and Guoyu Wang

Subjects
Shock wave, Materials science, Computer simulation, Turbulence, Mechanical Engineering, Flow (psychology), 02 engineering and technology, Mechanics, Condensed Matter Physics, Breakup, 01 natural sciences, 010305 fluids & plasmas, Physics::Fluid Dynamics, 020303 mechanical engineering & transports, 0203 mechanical engineering, Mechanics of Materials, Modeling and Simulation, Cavitation, 0103 physical sciences, Compressibility, Astrophysics::Galaxy Astrophysics, Water vapor
Abstract

The objective of this paper is to investigate the compressible turbulent cavitating flows with special emphasis on shock wave dynamics, with the water/vapor compressibility taken into account. The simulations are performed by solving the compressible, multiphase unsteady Reynolds-averaged Navier-Stokes equations with Saito cavitation model and SST-SAS turbulence model. The compressibility of both the pure water and vapor is considered by employment of the Tait equation of state for water and ideal gas equation of state for vapor. Results are presented for a 3-D NACA66 hydrofoil fixed at α = 6° and σ =1.25 in partial cavitating flows. Cavity collapse induced shock wave formation and propagation, which is closely related to the compressibility characteristics of cavitating flows, are well predicted. Good performance has been obtained for both the cavity evolution process and cavitation induced pressure signals, especially the cavity collapse induced shock wave emission and its interaction with the attached cavity sheet. The pressure peaks in microseconds accompanying the shock wave are captured. The typical quasi-periodic sheet/cloud cavitation evolution is characterized by the following four stages: (1) the growth of the attached cavity sheet, (2) development of re-entrant flow and attached cavity sheet breakup, (3) attached cavity sheet rolling up and cavity cloud shedding, and (4) cloud cavity collapse, shock wave emission and propagation. The cloud cavity collapse induced shock wave dynamics is supposed to be the major origin of cavitation instabilities.

Published
2018

156. New ideas and methods for the diagnosis and treatment of acute-on-chronic liver failure

Author

LI Shanshan, DUAN Zhongping, and CHEN Yu

Subjects
liver failure； hepatitis, liver cirrhosis, review, lcsh:Diseases of the digestive system. Gastroenterology, lcsh:RC799-869
Abstract

Acute-on-chronic liver failure (ACLF) is commonly seen in China and has a complex pathogenesis, difficult clinical treatment, and poor prognosis. ACLF has become a hot topic in the research on liver diseases in recent years. This article elaborates on the research advances in ACLF in China and foreign countries from the aspects of the definition, etiology, prognostic evaluation, and treatment regimens of ACLF, in order to provide new ideas and methods for clinical diagnosis and treatment, reduce mortality rate, and improve the clinical outcome of patients with ACLF.

Published
2018

160. Entecavir combined with interferon‐α Is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B.

Author

Cheng, Kailiang, Chen, Yu, Wang, Xiaomo, Xu, Manman, Liao, Wei, Duan, Xiaoman, Zhao, Xinyu, Sun, Yuanyuan, Duan, Zhongping, and Wang, Li

Subjects
CHRONIC hepatitis B, HEPATITIS associated antigen, LIVER cancer, HEPATOCELLULAR carcinoma, DISEASE risk factors
Abstract

Background: The objective of this study was to assess whether entecavir (ETV) in combination with interferon‐α (IFN‐α) could reduce hepatocellular cancer (HCC) and extrahepatic cancers (EHCs) in patients with chronic hepatitis B (CHB). Methods: The cohort consisted of 4194 patients with CHB treated with ETV combined with IFN‐α or ETV monotherapy at a tertiary hospital in Beijing, China, from January 2009 to December 2017. The risks, hazard ratios (HRs), and 95% confidence intervals (CIs) of HCC and EHCs were compared in the 2 groups. Results: In a multivariate Cox regression analysis, a significantly lower risk of HCC (HR, 0.6; 95% CI, 0.3‐0.9; P =.0310) and a marginally significantly lower risk of EHCs (HR, 0.2; 95% CI, 0.02‐1.3; P =.0854) were observed in the group receiving ETV combined with IFN‐α in comparison with the ETV monotherapy group. The annual virological response rates were significantly higher in the combination therapy group versus the monotherapy group (33.8% vs 21.2%; P <.0001), but the hepatitis B surface antigen (HBsAg) seroclearance rates were not (1.2% vs 0.9%; P =.8537). The HRs were consistent with propensity score–based matching, inverse probability weighting adjustments, and adjustments for virological response and HBsAg seroclearance. Conclusions: ETV combined with IFN‐α therapy is superior to ETV monotherapy in reducing the risk of HCC and EHCs for patients with CHB. People who can tolerate and benefit from IFN‐α therapy could consider combination therapy. This study finds a higher residual risk of hepatocellular cancer and extrahepatic cancers in those with entecavir monotherapy versus those with combined therapy. It is suggested that it is necessary to add interferon‐α for patients with chronic hepatitis B treated with entecavir to reduce the risk of cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

163. Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis

Author

Jiang, Yingying, primary, Tie, Cai, additional, Wang, Yang, additional, Bian, Dandan, additional, Liu, Mei, additional, Wang, Ting, additional, Ren, Yan, additional, Liu, Shuang, additional, Bai, Li, additional, Chen, Yu, additional, Duan, Zhongping, additional, Zheng, Sujun, additional, and Zhang, Jinlan, additional

Published
2020
Full Text
View/download PDF

167. Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: a large prospective cohort study

Author

Li, Yi, primary, Liu, Zhixiu, additional, Song, Yarong, additional, Xiao, Yiwei, additional, Jiang, Jing, additional, Li, Lili, additional, Zhai, Xiangjun, additional, Liu, Jianxun, additional, Duan, Zhongping, additional, Ding, Feng, additional, Liu, Jia, additional, Zhuang, Hui, additional, Zhu, Liguo, additional, Jiang, Jie, additional, Zou, Huaibin, additional, Wang, Jie, additional, and Li, Jie, additional

Published
2020
Full Text
View/download PDF

168. Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B

Author

Shan, Shan, primary, You, Hong, additional, Niu, Junqi, additional, Shang, Jia, additional, Xie, Wen, additional, Zhang, Yuexin, additional, Li, Xun, additional, Ren, Hong, additional, Tang, Hong, additional, Ding, Huiguo, additional, Wang, Xihong, additional, Nan, Yuemin, additional, Dou, Xiaoguang, additional, Han, Tao, additional, Zhang, Lingyi, additional, Liu, Xiaoqing, additional, Deng, Cunliang, additional, Cheng, Jilin, additional, Wang, Xiaozhong, additional, Xie, Qing, additional, Lin, Shumei, additional, Huang, Yan, additional, Xu, Youqing, additional, Xiong, Yong, additional, Li, Wu, additional, Yan, Xuebing, additional, Piao, Hongxin, additional, Huang, Wenxiang, additional, Lu, Qinghua, additional, Gong, Weijin, additional, Li, Shiping, additional, Hu, Xiaoxuan, additional, Zhang, Xiaolan, additional, Liu, Shourong, additional, Li, Yufang, additional, Yang, Dongliang, additional, Li, Hai, additional, Yang, Caixia, additional, Cheng, Mingliang, additional, Zhang, Liaoyun, additional, Zheng, Huanwei, additional, Luo, Xinhua, additional, Lin, Feng, additional, Wang, Lei, additional, Xu, Guanghua, additional, Xu, Xiaoyuan, additional, Wei, Lai, additional, Hou, Jinlin, additional, Duan, Zhongping, additional, Zhuang, Hui, additional, Yang, Xizhong, additional, Kong, Yuanyuan, additional, and Jia, Jidong, additional

Published
2019
Full Text
View/download PDF

173. Different drug metabolism behavior between species in drug-induced hepatotoxicity: limitations and novel resolutions.

Author

Han, Weijia and Duan, Zhongping

Subjects
DRUG metabolism, DRUG side effects, SPECIES specificity, DRUG development, EXTRACELLULAR matrix
Abstract

Drug-induced hepatotoxicity (DIH) in preclinical tests will help reduce drug attrition and development costs. However, the concordance between preclinical animal safety data and human clinical hepatotoxicity is <60%. Species specificity is an important reason. The main limitation caused by species specificity in DIH research is different mechanisms of drug metabolism. Therefore, in vitro models containing human-derived hepatocytes are needed in DIH research. Liver components, including non-parenchymal cells (NPCs), extracellular matrix (ECM) and continuously perfused environment, are essential for maintenance of hepatocyte metabolism. 3D ECM that contains human-derived hepatocytes and NPCs in a continuously perfused environment can be used to investigate drug metabolism in DIH research. In this review article, we summarize the different metabolic activities caused by species specificity in DIH research and describe current novel models, including 3D co-culture in vitro models, to circumvent differences in metabolic activity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

174. A HRGnovel mutation associated with idiopathic portal hypertension: Case report and literature review

Author

Tang, Shan, Bai, Li, Zhang, Wei, Song, Wenyan, Liu, Hui, Li, Lei, Liang, Chen, Duan, Zhongping, and Zheng, Sujun

Abstract

Idiopathic portal hypertension (IPH) is defined as the presence of portal hypertension in the absence of a common cause. IPH can have several etiologies, one of which is a genetic disorder. Some genetic mutations, such as KCNN3 and DGUOK, were shown to be related to IPH pathogenesis. This is the first case report of a 22-year-old man who was diagnosed with IPH with a novel heterozygous mutation in the histidine-rich glycoprotein gene (c.545G > C, p.R182T). Using bioinformatics analysis and the protein quantification method, we showed that this novel mutation has a pathogenetic role in IPH. Our study broadens the mutation spectrum of the histidine-rich glycoprotein gene and provides new ideas for IPH etiology.

Published
2022
Full Text
View/download PDF

175. Improvement of energy substrate metabolism by late evening snack supplementation in patients with liver cirrhosis: a meta-analysis

Author

Yao, Jia, Han, Weijia, Ren, Xiaojing, Yuan, Lili, Xu, Jun, and Duan, Zhongping

Subjects
branched-chain amino acid, Therapeutics and Clinical Risk Management, cirrhosis, energy metabolism, Original Research, late evening snack
Abstract

Jia Yao,1,* Weijia Han,2,3,* Xiaojing Ren,1 Lili Yuan,1 Jun Xu,1 Zhongping Duan2,31Department of Gastroenterology and General Surgery, Shanxi Dayi Hospital, Taiyuan, People’s Republic of China; 2Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, People’s Republic of China*These authors contributed equally to this workAim: Malnutrition is one of the most common complications in patients with liver cirrhosis. Abnormal energy substrate metabolism may contribute to aggravation of malnutrition. Late evening snack (LESs) supplementation has been recommended as an intervention to reduce starvation time and improve nutritional status. Published studies have analyzed the effect of LESs on the branched-chain amino acid (BCAA)/tyrosine ratio (BTR) and oxidation rate of fat and carbohydrate in patients with liver cirrhosis.Methods: We searched PubMed, Cochrane Library, Web of Science and Embase for relevant research from January 2000 to October 2018. The primary outcome for this analysis was changes in BTR and fat and carbohydrate oxidation in patients with liver cirrhosis.Results: A total of 9 articles, containing 211 patients, were included in this analysis. The results supported that supplementation with BCAA-enriched LESs improved BTR, and long-term supplementation with BCAAs (>1 month) may be more beneficial than short-term supplementation (

Published
2019

176. Improvement of energy substrate metabolism by late evening snack supplementation in patients with liver cirrhosis: a meta-analysis

Author

Yao,Jia, Han,Weijia, Ren,Xiaojing, Yuan,Lili, Xu,Jun, Duan,Zhongping, Yao,Jia, Han,Weijia, Ren,Xiaojing, Yuan,Lili, Xu,Jun, and Duan,Zhongping

Abstract

Jia Yao,1,* Weijia Han,2,3,* Xiaojing Ren,1 Lili Yuan,1 Jun Xu,1 Zhongping Duan2,31Department of Gastroenterology and General Surgery, Shanxi Dayi Hospital, Taiyuan, People’s Republic of China; 2Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, People’s Republic of China*These authors contributed equally to this work Aim: Malnutrition is one of the most common complications in patients with liver cirrhosis. Abnormal energy substrate metabolism may contribute to aggravation of malnutrition. Late evening snack (LESs) supplementation has been recommended as an intervention to reduce starvation time and improve nutritional status. Published studies have analyzed the effect of LESs on the branched-chain amino acid (BCAA)/tyrosine ratio (BTR) and oxidation rate of fat and carbohydrate in patients with liver cirrhosis.Methods: We searched PubMed, Cochrane Library, Web of Science and Embase for relevant research from January 2000 to October 2018. The primary outcome for this analysis was changes in BTR and fat and carbohydrate oxidation in patients with liver cirrhosis.Results: A total of 9 articles, containing 211 patients, were included in this analysis. The results supported that supplementation with BCAA-enriched LESs improved BTR, and long-term supplementation with BCAAs (>1 month) may be more beneficial than short-term supplementation (<1 month) in patients with liver cirrhosis. In addition, supplementation with BCAAs may increase the oxidation rate of carbohydrates and decrease the oxidation rate of fat. Furthermore, compared with liquid-enriched LESs, BCAA was a better choice for increasing the oxidation of carbohydrates and decreasing the rate of fat oxidation.Conclusion: BCAA-enriched LES supplementa

Published
2019

177. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China

Author

Pan, Calvin Q., Dai, Erhei, Duan, Zhongping, Han, Guorong, Zhao, Wenjing, Wang, Yuming, Zhang, Huaihong, Zhu, Baoshen, Jiang, Hongxiu, Zhang, Shuqin, Zhang, Xiaohu, Zou, Huaibin, Chen, Xiuli, and Chen, Yu

Abstract

ObjectiveThe physical and neuromental development of infants remains uncertain after fetal exposure to tenofovir disoproxil fumarate (TDF) for the prevention of mother-to-child transmission of HBV. We aimed to investigate the safety of TDF therapy during the third trimester of pregnancy.DesignInfants from a previous randomised controlled trial were recruited for our long-term follow-up (LTFU) study. Mothers with chronic hepatitis B were randomised to receive TDF therapy or no treatment during the third trimester. Infants’ physical growth or malformation, bone mineral density (BMD) and neurodevelopment, as assessed using Bayley-III assessment, were examined at 192 weeks of age.ResultsOf 180 eligible infants, 176/180 (98%) were enrolled and 145/176 (82%) completed the LTFU (control group: 75; TDF-treated group: 70). In the TDF-treated group, the mean duration of fetal exposure to TDF was 8.57±0.53 weeks. Congenital malformation rates were similar between the two groups at week 192. The mean body weight of boys in the control and TDF-treated groups was significantly higher (19.84±3.46 kg vs. 18.47±2.34 kg; p=0.03) and within the normal range (18.48±2.35 kg vs. 17.80±2.50 kg; p=0.07), respectively, when compared with the national standard. Other prespecified outcomes (head circumference, height, BMD, and cognitive, motor, social–emotional, and adaptive behaviour measurements) were all comparable between the groups.ConclusionInfants with fetal exposure to TDF had normal physical growth, BMD and neurodevelopment at week 192. Our findings provide evidence on the long-term safety of infants after fetal exposure to maternal TDF therapy for preventing hepatitis B transmission.Trial registration numberNCT01488526.

Published
2022
Full Text
View/download PDF

178. Therapeutic plasma‐exchange improves systemic inflammation and survival in acute‐on‐chronic liver failure: A propensity‐score matched study from AARC.

Author

Maiwall, Rakhi, Bajpai, Meenu, Choudhury, Ashok K., Kumar, Anupam, Sharma, Manoj Kumar, Duan, Zhongping, Yu, Chen, Hu, Jinhua, Ghazinian, Hasmik, Ning, Qin, Ma, Ke, Lee, Guan H., Lim, Seng G., Shah, Samir, Kalal, Chetan, Dokmeci, Abdulkadir, Kumar, Guresh, Jain, Priyanka, Rao Pasupuleti, Samba Siva, and Paulson, Irene

Subjects
LIVER failure, SYSTEMIC inflammatory response syndrome, INTERLEUKIN-1 receptors, CYTOKINE receptors, MULTIPLE organ failure
Abstract

Background and Aim: Plasma‐exchange (PE) has improved survival in acute liver failure by ameliorating systemic inflammatory response syndrome (SIRS). We evaluated PE and compared it to Fractional Plasma Separation and Adsorption (FPSA) and standard medical treatment (SMT) in a large multinational cohort of ACLF patients. Methods: Data were prospectively collected from the AARC database and analysed. Matching by propensity risk score (PRS) was performed. Competing risk survival analysis was done to identify deaths because of multiorgan failure (MOF). In a subset of 10 patients, we also evaluated the mechanistic basis of response to PE. Results: ACLF patients (n = 1866, mean age 44.3 ± 12.3 yrs, 93% males, 65% alcoholics) received either artificial liver support (ALS) (n = 162); [PE (n = 131), FPSA (n = 31)] or were continued on standard medical therapy (SMT) (n = 1704). In the PRS‐matched cohort (n = 208, [ALS‐119; PE‐94, FPSA‐25)], SMT‐89). ALS therapies were associated with a significantly higher resolution of SIRS (Odd's ratio 9.23,3.42‐24.8), lower and delayed development of MOF (Hazard ratio 7.1, 4.5‐11.1), and lower liver‐failure‐related deaths as compared to FPSA and SMT (P <.05). PE cleared inflammatory cytokines, damage‐associated molecular patterns, and endotoxin in all patients. Responders improved monocyte phagocytic function and mitochondrial respiration and increased the anti‐inflammatory cytokine interleukin‐1 receptor antagonist (IL‐1RA) compared to non‐responders. PE was associated with lesser adverse effects as compared to FPSA. Conclusions: PE improves systemic inflammation and lowers the development of MOF in patients with ACLF. Plasma‐exchange provides significant survival benefit over FPSA and could be a preferred modality of liver support for ACLF patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

179. Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

Author

Qian, Xiangjun, primary, Zheng, Sujun, additional, Wang, Leijie, additional, Yao, Mingjie, additional, Guan, Guiwen, additional, Wen, Xiajie, additional, Zhang, Ling, additional, Xu, Qiang, additional, Chen, Xiangmei, additional, Zhao, Jingmin, additional, Duan, Zhongping, additional, and Lu, Fengmin, additional

Published
2019
Full Text
View/download PDF

180. A novel xenograft model of human HCC in immunocompetent mouse

Author

Bi, Yanzhen, primary, Shi, Jun, additional, Li, Shanshan, additional, Wang, Quanyi, additional, Wang, Quanquan, additional, Wen, Xinyuan, additional, Yang, Feng, additional, Duan, Zhongping, additional, Yang, Yonghong, additional, Zhang, Xiaobei, additional, Zhang, Yongchao, additional, Shu, Zhenfeng, additional, Chen, Yu, additional, and Hong, Feng, additional

Published
2019
Full Text
View/download PDF

181. Quasispecies characteristic in “a” determinant region is a potential predictor for the risk of immunoprophylaxis failure of mother-to-child-transmission of sub-genotype C2 hepatitis B virus: a prospective nested case–control study

Author

Xiao, Yiwei, primary, Sun, Kuixia, additional, Duan, Zhongping, additional, Liu, Zhixiu, additional, Li, Yi, additional, Yan, Ling, additional, Song, Yarong, additional, Zou, Huaibin, additional, Zhuang, Hui, additional, Wang, Jie, additional, and Li, Jie, additional

Published
2019
Full Text
View/download PDF

183. Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C

Author

Wei, Lai, primary, Shang, Jia, additional, Ma, Yuanji, additional, Xu, Xiaoyuan, additional, Huang, Yan, additional, Guan, Yujuan, additional, Duan, Zhongping, additional, Zhang, Wenhong, additional, Gao, Zhiliang, additional, Zhang, Mingxiang, additional, Li, Jun, additional, Jia, Jidong, additional, Yang, Yongfeng, additional, Wen, Xiaofeng, additional, Wang, Maorong, additional, Jia, Zhansheng, additional, Ning, Bo, additional, Chen, Yongping, additional, Qi, Yue, additional, Du, Jie, additional, Jiang, Jianning, additional, Tong, Lixin, additional, Xie, Yao, additional, and Wu, Jinzi J., additional

Published
2019
Full Text
View/download PDF

187. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist

Author

Zhang, Xiaohui, primary, Liu, Bowei, additional, Tang, Liudi, additional, Su, Qing, additional, Hwang, Nicky, additional, Sehgal, Mohit, additional, Cheng, Junjun, additional, Ma, Julia, additional, Zhang, Xuexiang, additional, Tan, Yinfei, additional, Zhou, Yan, additional, Duan, Zhongping, additional, DeFilippis, Victor R., additional, Viswanathan, Usha, additional, Kulp, John, additional, Du, Yanming, additional, Guo, Ju-Tao, additional, and Chang, Jinhong, additional

Published
2019
Full Text
View/download PDF

189. THU-045-Natural history of sepsis, organ failure and organ dysfunction in critically ill patients with acute on chronic liver failure

Author

Mishra, Manjul, primary, Sarin, Shiv Kumar, additional, Rajan, Vijayraghavan, additional, Choudhury, Ashok, additional, Kumar, Guresh, additional, Jain, Priyanka, additional, Paulson, Irene, additional, Al-Mahtab, Mamun, additional, Rahman, Salimur, additional, Alam, Shahinul, additional, Devarbhavi, Harshad, additional, Chawla, Yogesh, additional, Dhiman, Radha Krishan, additional, Duseja, Ajay, additional, Taneja, Sunil, additional, Ning, Qin, additional, Ma, Ke, additional, Chen, Tao, additional, Duan, Zhongping, additional, Chen, Yu, additional, Eapen, Ce, additional, Goel, Ashish, additional, Tan, Soek-Siam, additional, Hamid, Saeed Sadiq, additional, Subhan, Amna, additional, Jafri, Wasim, additional, Kim, DongJoon, additional, Hu, Jinhua, additional, Amarapurkar, Deepak, additional, Sood, Ajit, additional, Midha, Vandana, additional, Goyal, Omesh, additional, Shukla, Akash, additional, Ghazinian, Hasmik, additional, Sahoo, Manoj, additional, Treeprasertsuk, Sombat, additional, Lee, Guan Huei, additional, Lim, Seng Gee, additional, Lesmana, Laurentius A., additional, Lesmana, Rinaldi, additional, Shah, Samir, additional, Kalal, Chetan, additional, Abbas, Zaigham, additional, s, Joyes, additional, Carpio, Gian, additional, GM, V, additional, Payawal, Diana, additional, Dokmeci, A. Kadir, additional, Shrestha, Ananta, additional, Lau, George, additional, and Yuen, Man-Fung, additional

Published
2019
Full Text
View/download PDF

190. FRI-161-Complication is a major risk factor for mortality of cirrhotic hepatitis B virus-related acuted-on-chronic liver failure patients: A multi-national study from Asian-pacific region

Author

Chen, Tao, primary, Yang, Zhongyuan, additional, Li, Jun, additional, Han, Tao, additional, Hu, Jinhua, additional, Xin, Shaojie, additional, Choudhury, Ashok, additional, Al-Mahtab, Mamun, additional, Nan, Yuemin, additional, Tan, Soek-Siam, additional, Hamid, Saeed Sadiq, additional, Subhan, Amna, additional, Jafri, Wasim, additional, Lee, Guan Huei, additional, Ghazinian, Hasmik, additional, Chawla, Yogesh, additional, Yuen, Man-Fung, additional, Jia, Ji-Dong, additional, Abbas, Zaigham, additional, Devarbhavi, Harshad, additional, Kadir Dokmeci, A., additional, Amarapurkar, Deepak, additional, Kumar, Manoj, additional, Lesmana, Laurentius A., additional, Lau, George, additional, Yokosuka, Osamu, additional, Duan, Zhongping, additional, Guo, Wei, additional, Ma, Ke, additional, Zhang, Zhongwei, additional, Sarin, Shiv Kumar, additional, and Ning, Qin, additional

Published
2019
Full Text
View/download PDF

191. THU-053-Usefulness of lactate-free Asian Pacific Association for The Study of Liver acute-on-chronic liver failure research consortium ACLF score for predicting short-term mortality in patient with alcoholic liver disease

Author

Song, Do Seon, primary, Kim, Tae Yeob, additional, Kim, Hee Yeon, additional, Yoon, Eileen L, additional, Kim, Dong Joon, additional, Jia, Ji-Dong, additional, Choudhury, Ashok, additional, Al-Mahtab, Mamun, additional, Devarbhavi, Harshad, additional, Duan, Zhongping, additional, Chen, Yu, additional, Eapen, CE, additional, Goel, Ashish, additional, Ning, Qin, additional, Ma, Ke, additional, Chawla, Yogesh, additional, Dhiman, Radha Krishan, additional, Duseja, Ajay, additional, Taneja, Sunil, additional, Hamid, Saeed Sadiq, additional, Subhan, Amna, additional, Jafri, Wasim, additional, Tan, Soek-Siam, additional, Ghazinian, Hasmik, additional, Amarapurkar, Deepak, additional, Treeprasertsuk, Sombat, additional, Lee, Guan Huei, additional, Lim, Seng Gee, additional, Hu, Jinhua Hu, additional, Lesmana, Laurentius A., additional, Lesmana, Rinaldi, additional, Shukla, Akash, additional, Shah, Samir, additional, Kalal, Chetan, additional, Sahoo, Manoj, additional, Abbas, Zaigham, additional, s, Joyes, additional, Carpio, Gian, additional, Karim, Md. Fazal, additional, Lau, George, additional, Padaki, Nagaraja Rao, additional, Payawal, Diana, additional, Kadir Dokmeci, A., additional, Yuen, Man-Fung, additional, GM, V, additional, Yokosuka, Osamu, additional, Shrestha, Ananta, additional, Jain, Priyanka, additional, Paulson, Irene, additional, and Sarin, Shiv Kumar, additional

Published
2019
Full Text
View/download PDF

196. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

Author

Wei, Lai, primary, Lim, Seng Gee, additional, Xie, Qing, additional, Văn, Kính Nguyen, additional, Piratvisuth, Teerha, additional, Huang, Yan, additional, Wu, Shanming, additional, Xu, Ming, additional, Tang, Hong, additional, Cheng, Jun, additional, Le Manh, Hung, additional, Gao, Yanhang, additional, Mou, Zhuangbo, additional, Sobhonslidsuk, Abhasnee, additional, Dou, Xiaguang, additional, Thongsawat, Satawat, additional, Nan, Yuemin, additional, Tan, Chee Kiat, additional, Ning, Qin, additional, Tee, Hoi Poh, additional, Mao, Yimin, additional, Stamm, Luisa M, additional, Lu, Sophia, additional, Dvory-Sobol, Hadas, additional, Mo, Hongmei, additional, Brainard, Diana M, additional, Yang, Yong-Feng, additional, Dao, Long, additional, Wang, Gui-Qiang, additional, Tanwandee, Tawesak, additional, Hu, Peng, additional, Tangkijvanich, Pisit, additional, Zhang, Lunli, additional, Gao, Zhi Liang, additional, Lin, Feng, additional, Le, Thi Tuyet Phuong, additional, Shang, Jia, additional, Gong, Guozhong, additional, Li, Jun, additional, Su, Minghua, additional, Duan, Zhongping, additional, Mohamed, Rosmawati, additional, Hou, Jin Lin, additional, and Jia, Jidong, additional

Published
2019
Full Text
View/download PDF

197. Human liver stem cells attenuate concanavalin A-induced acute liver injury by modulating myeloid-derived suppressor cells and CD4+ T cells in mice

Author

Bi, Yanzhen, primary, Li, Jiannan, additional, Yang, Yonghong, additional, Wang, Quanyi, additional, Wang, Quanquan, additional, Zhang, Xiaobei, additional, Dong, Guanjun, additional, Wang, Yibo, additional, Duan, Zhongping, additional, Shu, Zhenfeng, additional, Liu, Tongjun, additional, Chen, Yu, additional, Zhang, Kai, additional, and Hong, Feng, additional

Published
2019
Full Text
View/download PDF

198. Artificial Liver Treatment Improves Survival in Patients with Acute-on-Chronic Liver Failure

Author

Yang, Lingling, primary, Wu, Tianzhou, additional, Li, Jiang, additional, Xin, Jiaojiao, additional, Shi, Dongyan, additional, Jiang, Jing, additional, Liang, Xi, additional, Lu, Yingyan, additional, Yao, Heng, additional, Zhang, Huafen, additional, Sun, Suwan, additional, Li, Tan, additional, Hassan Mohamed, Hozeifa Mohamed, additional, Li, Jiaqi, additional, Ren, Keke, additional, Guo, Beibei, additional, Zhou, Xingping, additional, Chen, Jiaxian, additional, Hao, Shaorui, additional, Chen, Jiajia, additional, Xin, Shaojie, additional, Pan, Chen, additional, Han, Tao, additional, Chen, Yongping, additional, Lin, Shumei, additional, Duan, Zhongping, additional, Xu, Xiaowei, additional, Huang, Jianrong, additional, Chen, Xin, additional, Li, Lanjuan, additional, Li, Jun, additional, and Group, Chinese Group on the Study of Sever, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results